Meet the Team

---

CEO Jim Hauert has over 25 years of global healthcare experience. His focus has been on the commercialization of new technologies in highly competitive markets. With a blend of Fortune 500 and entrepreneurial experience, he has a proven track record of creating and executing high-value business plans that have resulted in multiple billion-dollar businesses and leading product brands.

Mr. Hauert obtained his Master of Business Administration from Lake Forest Graduate School and a Bachelor of Science in Accountancy from DePaul University.

Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized diagnostics. His efforts focus on the discovery and validation of biomarkers — unique molecular fingerprints of disease — which can provide early warning for those at risk of major illnesses, including cancer and diabetes.

Formerly founder and director of the Harvard Institute of Proteomics, LaBaer was recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine in 2009. The Virginia G. Piper Center for Personalized Diagnostics has a highly multidisciplinary staff of molecular biologists, cell biologists, biochemists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers.

LaBaer applies open reading frame clones to the high throughput (HT) study of protein function. In addition, his group invented a novel protein microarray technology, Nucleic Acid Programmable Protein Array, which has been used widely for biomedical research, including the recent discovery of a panel of 28 autoantibody biomarkers that led to the development of Videssa™, the first CLIA-certified blood test for breast cancer.

LaBaer earned his medical degree and a doctorate in biochemistry and biophysics, from the University of California, San Francisco. He completed his medical residency at the Brigham and Women’s Hospital and a clinical fellowship in oncology at the Dana-Farber Cancer Institute, both in Boston. He has contributed more than 150 original research publications, reviews and chapters.

LaBaer is an associate editor of the Journal of Proteome Research, a recent member of the National Cancer Institute’s Board of Scientific Advisors, Chair of the Early Detection Research Network Steering Committee and recent president of the U.S. Human Proteome Organization. Dr. LaBaer a member of the board of directors for the American Type Culture Collection (ATCC) and serves on the Scientific Advisory Boards Nautilus Biotechnology  Abpro, and Provista Diagnostics.

 Ji Qiu is a Research Professor at the Center for Personalized Diagnostics at Arizona State University. His research focuses on the development of novel functional proteomics technologies and the application of these technologies to biomedical research. He has over 15 years of experiences in biomarker discovery in various diseases including cancers, infectious and autoimmune diseases under different clinical settings. He received his Ph.D. degree from the University of Texas at Austin. After his post-doctoral training at the University of Michigan, he pursued research interests at Fred Hutchinson Cancer Research Center in the area of molecular diagnostics. He joined ASU in the fall of 2009.